Diabetic Retinopathy
Author:
Bowie E.,Crosson C. E.
Reference91 articles.
1. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, et al. 2006. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113: 23–28.
2. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, et al. 1996. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114: 66–71.
3. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, et al. 2006. Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 47: 86–92.
4. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. 1999. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascularpermeability in diabetic retinopathy and tumors. J Biol Chem 274: 23463–23467.
5. Antonetti DA, Wolpert EB, De Maio L, Harhaj NS, Scaduto RC Jr. 2002. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 80: 667–677.